Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03266588 at ClinicalTrials.govDocuments that mention this clinical trial
Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study
https://doi.org/10.1007/s40122-024-00675-6
Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study
https://doi.org/10.1007/s40122-024-00626-1
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
https://doi.org/10.1007/s12325-021-01897-2
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 19 April 2024
Accepted: 5 June 2024
First Online: 10 July 2024
Declarations
:
: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. David True has served as a principal investigator for headache trials for Allergan, AbbVie, electroCore, Eli Lilly, Teva, Theranica, Ionis, Avanir, Amgen, Aeon, Alder, Lundbeck, Axsome, Mayo Clinic, Nocira, Satsuma, Zosano, Tonix, and Pfizer. Kathleen Mullin serves as a consultant or advisory board member for or has received honoraria from Amgen, Biohaven, electroCore, and Eli Lilly. Robert Croop was an employee of Biohaven Pharmaceuticals, owns stock in Biohaven Ltd, was an employee of Pfizer, has received research payments from Pfizer, and provides services to Collima LLC, which has had consulting agreements with Pfizer, Actio Biosciences, Inc., Aptose Biosciences Inc., Biohaven Pharmaceuticals, Inc., Manistee Therapeutics, and Vida Ventures Management Co., LLC.
: The study was conducted in accordance with Good Clinical Practice, as defined by the International Conference on Harmonisation, Good Laboratory Practice, the Declaration of Helsinki, and all applicable regulations. All participants provided written informed consent prior to participation in the study. The protocol was approved by Institutional Review Boards (Advarra IRB [IRB00000971], Schulman Associates IRB [IRB00007642; acquired by Advarra], and Biomedical Research Alliance New York [BRANY] IRB [IRB00000080]) before the start of the study.
